Clinical trial
Predicting the Response to Montelukast by Genetic Variation in Asthmatics
NCT00116324 · Brigham and Women's Hospital, Other · Completed
Key facts
| NCT number | NCT00116324 |
|---|---|
| Title | Predicting the Response to Montelukast by Genetic Variation in Asthmatics |
| Official title | Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism |
| Lead sponsor | Brigham and Women's Hospital, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Montelukast |
| Enrollment | 150 |
| Start date | Apr 1, 2003 |
| Completion | Dec 1, 2006 |
| First posted | Jun 29, 2005 |
| Last update posted | May 18, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: